Blinded by Stress: A Patient and Physician Perspective on Central Serous Chorioretinopathy.
Central serous chorioretinopathy
Stress
Visual symptoms
Journal
Ophthalmology and therapy
ISSN: 2193-8245
Titre abrégé: Ophthalmol Ther
Pays: England
ID NLM: 101634502
Informations de publication
Date de publication:
22 Feb 2024
22 Feb 2024
Historique:
received:
17
01
2024
accepted:
05
02
2024
medline:
22
2
2024
pubmed:
22
2
2024
entrez:
22
2
2024
Statut:
aheadofprint
Résumé
This commentary is co-authored by a patient with central serous chorioretinopathy (CSC), which is the fourth most common exudative maculopathy. The patient, a young and profiled member of the Danish Parliament, kindly shares his experience living with stress, onset of symptoms, and the experience of being diagnosed with CSC and receiving photodynamic treatment. The experiences of the patient are put into perspective by an ophthalmologist. In this patient–physician perspective, a patient with central serous chorioretinopathy shares his experience. Central serous chorioretinopathy mainly affects men aged 30–50, is associated with stress, and the main symptom is blurring of central vision. The patient describes his life and work as member of the Danish Parliament, living with stress, being diagnosed with central serous chorioretinopathy, receiving treatment, and finally adapting to a new life in which work–life balance is prioritized to avoid excessive stress.
Autres résumés
Type: plain-language-summary
(eng)
In this patient–physician perspective, a patient with central serous chorioretinopathy shares his experience. Central serous chorioretinopathy mainly affects men aged 30–50, is associated with stress, and the main symptom is blurring of central vision. The patient describes his life and work as member of the Danish Parliament, living with stress, being diagnosed with central serous chorioretinopathy, receiving treatment, and finally adapting to a new life in which work–life balance is prioritized to avoid excessive stress.
Identifiants
pubmed: 38386185
doi: 10.1007/s40123-024-00907-0
pii: 10.1007/s40123-024-00907-0
doi:
Types de publication
Journal Article
Langues
eng
Informations de copyright
© 2024. The Author(s).
Références
van Rijssen TJ, van Dijk EHC, Yzer S, et al. Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retin Eye Res. 2019;73:100770.
doi: 10.1016/j.preteyeres.2019.07.003
pubmed: 31319157
Fine SL, Owens SL. Central serous retinopathy in a 7-year-old girl. Am J Ophthalmol. 1980;90:871–3.
doi: 10.1016/S0002-9394(14)75205-5
pubmed: 7446676
Spaide RF, Campeas L, Haas A, et al. Central serous chorioretinopathy in younger and older adults. Ophthalmology. 1996;103:2070–9.
doi: 10.1016/S0161-6420(96)30386-2
pubmed: 9003341
Kitzmann AS, Pulido JS, Diehl NN, Hodge DO, Burke JP. The incidence of central serous chorioretinopathy in Olmsted County, Minnesota, 1980–2002. Ophthalmology. 2008;115:169–73.
doi: 10.1016/j.ophtha.2007.02.032
pubmed: 18166410
Rim TH, Kim HS, Kwak J, Lee JS, Kim DW, Kim SS. Association of corticosteroid use with incidence of central serous chorioretinopathy in South Korea. JAMA Ophthalmol. 2018;136:1164–9.
doi: 10.1001/jamaophthalmol.2018.3293
pubmed: 30098167
pmcid: 6233821
Von Graefe A. Ueber zentrale recidivierende retinitis. Graefes Arch Clin Exp Ophthalmol. 1866;12:211–5.
Bennett G. Central serous retinopathy. Br J Ophthalmol. 1955;39:605–18.
doi: 10.1136/bjo.39.10.605
pubmed: 13260557
pmcid: 1324597
Carvalho-Recchia CA, Yannuzzi LA, Negrão S, et al. Corticosteroids and central serous chorioretinopathy. Ophthalmology. 2002;109:1834–7.
doi: 10.1016/S0161-6420(02)01117-X
pubmed: 12359603
Holtz JK, Larsson JME, Hansen MS, van Dijk EHC, Subhi Y. Pachychoroid spectrum diseases in patients with Cushing’s syndrome: a systematic review with meta-analyses. J Clin Med. 2022;11:4437.
doi: 10.3390/jcm11154437
pubmed: 35956052
pmcid: 9369356
Subhi Y, Windfeld-Mathiasen J, Horwitz A, Horwitz H. Risk of central serous chorioretinopathy in male androgen abusers. Ophthalmol Ther. 2023;12:1073–80.
doi: 10.1007/s40123-023-00658-4
pubmed: 36692812
pmcid: 10011293
Brinks J, van Dijk EHC, Meijer OC, Schlingemann RO, Boon CJF. Choroidal arteriovenous anastomoses: a hypothesis for the pathogenesis of central serous chorioretinopathy and other pachychoroid disease spectrum abnormalities. Acta Ophthalmol. 2022;100:946–59.
doi: 10.1111/aos.15112
pubmed: 35179828
pmcid: 9790326
Spaide RF, Gemmy Cheung CM, Matsumoto H, et al. Venous overload choroidopathy: a hypothetical framework for central serous chorioretinopathy and allied disorders. Prog Retin Eye Res. 2022;86:100973.
doi: 10.1016/j.preteyeres.2021.100973
pubmed: 34029721
Prünte C. Indocyanine green angiographic findings in central serous chorioretinopathy. Int Ophthalmol. 1995;19:77–82.
doi: 10.1007/BF00133176
pubmed: 8586500
Scholz P, Altay L, Sitnilska V, et al. Salivary alpha-amylase levels may correlate with central serous chorioretinopathy activity. Retina. 2021;41:2479–84.
doi: 10.1097/IAE.0000000000003266
pubmed: 34292222
Cassel GH, Brown GC, Annesley WH. Central serous chorioretinopathy: a seasonal variation? Br J Ophthalmol. 1984;68:724–6.
doi: 10.1136/bjo.68.10.724
pubmed: 6477852
pmcid: 1040453
Kida T, Kobayashi T, Sato T, Fukumoto M, Ikeda T. Seasonal variation in Japanese central serous chorioretinopathy. Ophthalmologica. 2018;240:150–6.
doi: 10.1159/000492136
pubmed: 30149372
Borrelli E, Viganò C, Battista M, et al. Individual vs. combined imaging modalities for diagnosing neovascular central serous chorioretinopathy. Graefes Arch Clin Exp Ophthalmol. 2023;261:1267–73.
doi: 10.1007/s00417-022-05924-y
pubmed: 36441229
Elfandi S, Ooto S, Miyata M, et al. Effects of intravitreous aflibercept injection in pachychoroid neovasculopathy: comparison with typical neovascular age-related macular degeneration. Clin Ophthalmol. 2021;15:1539–49.
doi: 10.2147/OPTH.S285257
pubmed: 33883872
pmcid: 8054474
Mohabati D, van Rijssen TJ, van Dijk EH, et al. Clinical characteristics and long-term visual outcome of severe phenotypes of chronic central serous chorioretinopathy. Clin Ophthalmol. 2018;12:1061–70.
doi: 10.2147/OPTH.S160956
pubmed: 29922035
pmcid: 5995302
Hata M, Oishi A, Shimozono M, Mandai M, Nishida A, Kurimoto Y. Early changes in foveal thickness in eyes with central serous chorioretinopathy. Retina. 2013;33:296–301.
doi: 10.1097/IAE.0b013e31826710a0
pubmed: 23023530
van Dijk EHC, Feenstra HMA, Bjerager J, Grauslund J, Boon CJF, Subhi Y. Comparative efficacy of treatments for chronic central serous chorioretinopathy: a systematic review with network meta-analyses. Acta Ophthalmol. 2023;101:140–59.
doi: 10.1111/aos.15263
pubmed: 36178171
van Rijssen TJ, van Dijk EHC, Scholz P, et al. Crossover to photodynamic therapy or micropulse laser after failure of primary treatment of chronic central serous chorioretinopathy: the REPLACE trial. Am J Ophthalmol. 2020;216:80–9.
doi: 10.1016/j.ajo.2020.04.007
pubmed: 32289294
Iwase T, Yokouchi H, Kitahashi M, Kubota-Taniai M, Baba T, Yamamoto S. Long-term effects of half-time photodynamic therapy on retinal sensitivity in eyes with chronic central serous chorioretinopathy. Biomed Res Int. 2020;2020:3190136.
doi: 10.1155/2020/3190136
pubmed: 32908883
pmcid: 7450301
Sirks MJ, van Dijk EHC, Rosenberg N, et al. Clinical impact of the worldwide shortage of verteporfin (Visudyne®) on ophthalmic care. Acta Ophthalmol. 2022;100:e1522–32.
doi: 10.1111/aos.15148
pubmed: 35388619
pmcid: 9790583
Riiskjær E, Ammentorp J, Nielsen JF, Kofoed PE. Hospitals need to customise care according to patients’ differing information-seeking behaviour. Dan Med J. 2014;61:A4787.
pubmed: 24495891
Li F, Li M, Guan P, Ma S, Cui L. Mapping publication trends and identifying hot spots of research on Internet health information seeking behavior: a quantitative and co-word biclustering analysis. J Med Internet Res. 2015;17:e81.
doi: 10.2196/jmir.3326
pubmed: 25830358
pmcid: 4390616
Borgersen NJ, Henriksen MJ, Konge L, Sørensen TL, Thomsen AS, Subhi Y. Direct ophthalmoscopy on YouTube: analysis of instructional YouTube videos’ content and approach to visualization. Clin Ophthalmol. 2016;10:1535–41.
doi: 10.2147/OPTH.S111648
pubmed: 27574393
pmcid: 4993418
Subhi Y, Bube SH, Rolskov Bojsen S, Skou Thomsen AS, Konge L. Expert involvement and adherence to medical evidence in medical mobile phone apps: a systematic review. JMIR Mhealth Uhealth. 2015;3:e79.
doi: 10.2196/mhealth.4169
pubmed: 26215371
pmcid: 4705370
Rasmussen MLR, Larsen AC, Subhi Y, Potapenko I. Artificial intelligence-based ChatGPT chatbot responses for patient and parent questions on vernal keratoconjunctivitis. Graefes Arch Clin Exp Ophthalmol. 2023;261:3041–3.
doi: 10.1007/s00417-023-06078-1
pubmed: 37129631
Potapenko I, Malmqvist L, Subhi Y, Hamann S. Artificial intelligence-based ChatGPT responses for patient questions on optic disc drusen. Ophthalmol Ther. 2023;12:3109–19.
doi: 10.1007/s40123-023-00800-2
pubmed: 37698823
pmcid: 10640407
Potapenko I, Boberg-Ans LC, Stormly Hansen M, Klefter ON, van Dijk EHC, Subhi Y. Artificial intelligence-based chatbot patient information on common retinal diseases using ChatGPT. Acta Ophthalmol. 2023;101:829–31.
doi: 10.1111/aos.15661
pubmed: 36912780
Larsson JME, Boberg-Ans LC, Vangsted A, et al. Topical non-steroidal anti-inflammatory drugs for central serous chorioretinopathy: a systematic review and meta-analysis. Acta Ophthalmol. 2023. https://doi.org/10.1111/aos.15743 .
doi: 10.1111/aos.15743
pubmed: 38148500